DoctoRx
Special situations, growth at reasonable price, value, micro-cap

Portola: A Small Biotech Stock That Could Double - And Then Double Again

Background: The biotech/biopharma space is coming of age. An expanding pool of seasoned executives is finding improved science-based targets with what strikes me as improved R&D efficiency.

This situation is meeting a favorable macro milieu, with rich societies willing to, if necessary, inflate the money supply to provide what tend to often be generous reimbursements for important drug products that improve the treatment of existing diseases.

This backdrop suggests that investors of a certain degree of adventurousness may consider buying shares in biotech companies with products advanced enough in development that revenues and profits can be estimated. Therefore, shares of development-stage companies to be reasonable investments - in my view. (Note that I am not an investment adviser.)

One...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details